| A43 | SARS-Cov-2 immunity in COVID-19 convalescent individuals living with HIV: bulk immune profiling and SARS-CoV-2 specific humoral and cellular immune responses | Oral abstract session with live Q&A | Co-infection: SARS-Co-V2 |
| A43 | SARS-CoV-2-seronegative subjects target CTL epitopes in the SARS-CoV-2 nucleoprotein cross-reactive to common cold coronaviruses | Oral abstract session with live Q&A | Co-infection: SARS-Co-V2 |
| A41 | Viral hepatitis cascade of care among adults living with HIV in Asia-Pacific | Oral abstract session with live Q&A | Co-infection: Viral hepatitis |
| A18 | In-vivo imaging using anti-ENV probes in SIV infected monkeys: a reproducibility study | Oral abstract session with live Q&A | Cellular and tissue reservoirs of HIV/SIV |
| A22 | Dual IL-10 and PD-1 blockade in SIVmac239 infected macaques promotes sustained virologic control in absence of ART | Oral abstract session with live Q&A | Immunotherapy: Immune-Modifying Agents |
| A20 | Combination therapy with the broadly neutralizing antibody VRC07'523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+ T cell infection or reduce low-level viremia | Oral abstract session with live Q&A | Eliminating and silencing latency |
| A18 | The passenger hypothesis: HIV exploits CD4 T cell homeostasis to promote long-term persistence of its reservoirs | Oral abstract session with live Q&A | Cellular and tissue reservoirs of HIV/SIV |
| A17 | Identifying host genetic determinants of HIV-1 reservoir markers reveals PTDSS2 and IRF7 as potential modifying factors in HIV-1 patients | Oral abstract session with live Q&A | Host cellular factors and latency |
| A18 | Naïve CD4+ T cells form the bulk of the translation competent HIV-1 reservoir in vertically infected children and adolescents | Oral abstract session with live Q&A | Cellular and tissue reservoirs of HIV/SIV |
| B11 | Early termination of randomisation into TB-PRACTECAL, a novel six months all-oral regimen Drug Resistant TB study | Oral abstract session with live Q&A | Tuberculosis and other mycobacteria |